Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauri E Markowitz

Showing results (281-290 of 290) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 290 results.
MMWR. Morbidity and Mortality Weekly Report|February 27, 2025
Trends in Cervical Precancers Identified Through Population-Based Surveillance - Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008-2022Julia W Gargano, Ruth Stefanos, Rebecca M Dahl, et al.
MMWR. Morbidity and Mortality Weekly Report|July 8, 2021
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021Julia W Gargano, Megan Wallace, Stephen C Hadler, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccinationSuchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, et al.
MMWR. Morbidity and Mortality Weekly Report|January 20, 2022
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021Sara E Oliver, Megan Wallace, Isaac See, et al.
MMWR. Morbidity and Mortality Weekly Report|August 12, 2021
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021Hannah G Rosenblum, Stephen C Hadler, Danielle Moulia, et al.
Vaccine|February 10, 2024
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemicLauri E Markowitz, Robert H Hopkins, Karen R Broder, et al.
Vaccine|November 16, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Pageof 29

Showing results (281-290 of 290) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 290 results.
MMWR. Morbidity and Mortality Weekly Report|February 27, 2025
Trends in Cervical Precancers Identified Through Population-Based Surveillance - Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008-2022Julia W Gargano, Ruth Stefanos, Rebecca M Dahl, et al.
MMWR. Morbidity and Mortality Weekly Report|July 8, 2021
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021Julia W Gargano, Megan Wallace, Stephen C Hadler, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccinationSuchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, et al.
MMWR. Morbidity and Mortality Weekly Report|January 20, 2022
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021Sara E Oliver, Megan Wallace, Isaac See, et al.
MMWR. Morbidity and Mortality Weekly Report|August 12, 2021
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021Hannah G Rosenblum, Stephen C Hadler, Danielle Moulia, et al.
Vaccine|February 10, 2024
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemicLauri E Markowitz, Robert H Hopkins, Karen R Broder, et al.
Vaccine|November 16, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Pageof 29